NASAL POLYPS TREATMENT MARKET ANALYSIS
Market players are getting approvals from regulatory bodies for new drugs, which is expected to drive growth of global nasal polyps treatment market, over the forecast period. For instance, on July 29, 2021, GlaxoSmithKline plc, a pharmaceutical and biotechnology company, got an approval from the U.S. Food and Drug Administration for its drug Nucala (mepolizumab) used for the treatment of patients with chronic rhinosinusitis with nasal polyps. Mepolizumab, is a monoclonal antibody that targets interleukin-5. Mepolizumab is the first IL-5 remedy accepted as an add-on treatment in the U.S. for adults with chronic rhinosinusitis with nasal polyps to aim eosinophilic inflammation.
Product approvals by regulatory bodies are expected to drive growth of the global nasal polyps treatment market over the forecast period. For instance, on December 1, 2020, Novartis, a pharmaceutical company, had announced that the U.S. Food and Drug Administration had approved its product Xolair (omalizumab). Xolair is used for the treatment of nasal polyps in adult patients. Xolair is the first biologic for the treatment of nasal polyps that aims and blocks immunoglobulin E (IgE).
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :